ST Pharm
Seoul, South Korea
No confirmed program data — ClinicalTrials.gov verification pending
· Last scored 2026-09-07
73.2
Signal Score
○ FDA Inspections
○ Clinical Trials
○ SEC Filings
✓ Press (13)
○ EMA GMP
○ MHRA GMP
Quick Facts: ST Pharm
- Signal Score
- 73.2/100 (as of 2026-09-07)
- Quality Compliance
- 89.4/100
- Headquarters
- Seoul, South Korea
- Modalities
- Oligonucleotide, mRNA
- Active Programs
- Data pending
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
- Scored By
- CDMO Signal — independent CDMO intelligence platform
About ST Pharm
Pure-play CDMO.
Signal Score & Pillar Breakdown
Scores are being republished.
Scores are being republished under methodology v3.3. The score shown is the last complete v3.2 result, which is also what directory listings and search results show. A pillar breakdown is not shown because the current one is computed under v3.3 and would not explain a v3.2 score. Regulatory evidence below is current.
Quality Compliance
89.4
FDA InspectionsNo US records on file
Operations
—
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs
— no verified data
Sponsors— no verified data
ModalitiesOligonucleotide, mRNA
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Financial Stability
60.0
Profile-based financial assessment
SEC FilingsPrivate company
Capacity
58.0
Profile-based capacity assessment
Recent Press13 articles
Attribution not established
(6)
These records are excluded from this company’s established evidence
because their attribution is unresolved. This describes an evidence-linking
limitation, not an assessment of the underlying regulatory findings.
| Source | Establishment named by the regulator | Location | Identifier |
|---|---|---|---|
| FDA inspection | Pharbest Pharmaceuticals, Inc. | Farmingdale, New York | FDA/FEI=3005382247 |
| FDA inspection | Steri-Pharma, LLC | Syracuse, New York | FDA/FEI=3008585015 |
| EMA GMP certificate | Best Pharm a.s. | Prague | EMA_OMS/OMS_LOCATION_ID=LOC-100020892 |
| EMA GMP certificate | Best Pharm a.s. | Prague | EMA_OMS/OMS_LOCATION_ID=LOC-100020892 |
| EMA GMP certificate | Biotest Pharma GmbH | Dreieich | — |
| EMA GMP certificate | West Pharmaceutical Products Ireland Limited | Waterford | — |
Source records retained verbatim · attribution not established
Recent News 13 articles
ST Pharm First-Quarter Operating Profit Surges Tenfold - thelec.net
ST Pharm First-Quarter Operating Profit Surges Tenfold thelec.net
Dong-A group's Q1 sales rise as ST Pharm, Dong-A ST profits climb - koreabiomed.com
Dong-A group's Q1 sales rise as ST Pharm, Dong-A ST profits climb koreabiomed.com
ST Pharm Secures Japanese Patent for Key LNP Material 'STP1244' - 아시아경제
ST Pharm Secures Japanese Patent for Key LNP Material 'STP1244' - The Asia Business Daily 아시아경제
ST Pharm Poised for Order Surge as RNA Therapeutics Market Expands - 서울경제신문
ST Pharm Poised for Order Surge as RNA Therapeutics Market Expands Seoul Economic Daily
ST Pharm Poised for Order Surge as RNA Therapeutics Market Expands - Seoul Economic Daily
ST Pharm Poised for Order Surge as RNA Therapeutics Market Expands Seoul Economic Daily
ST Pharm Signs Record 89.7 Billion Won Oligonucleotide Contract - Businesskorea
ST Pharm Signs Record 89.7 Billion Won Oligonucleotide Contract Businesskorea
ST Pharm lands record-breaking single CMO order worth KRW 89.7 billion from global pharmaceutical giant - 더바이오
ST Pharm lands record-breaking single CMO order worth KRW 89.7 billion from global pharmaceutical giant 더바이오
ST Pharm secures record oligo API deal with European drugmaker - CHOSUNBIZ - Chosunbiz
ST Pharm secures record oligo API deal with European drugmaker - CHOSUNBIZ Chosunbiz
ST Pharm Signs KRW 89.7 Billion Oligonucleotide Order, Largest Single Contract to Date - 아시아경제
ST Pharm Signs KRW 89.7 Billion Oligonucleotide Order, Largest Single Contract to Date 아시아경제
ST Pharm to produce non-clinical samples for Nipah virus mRNA vaccine - koreabiomed.com
ST Pharm to produce non-clinical samples for Nipah virus mRNA vaccine koreabiomed.com
ST Pharm Begins Production of Nipah Virus mRNA Vaccine Samples - 아시아경제
ST Pharm Begins Production of Nipah Virus mRNA Vaccine Samples 아시아경제
ST Pharm begins Nipah mRNA vaccine preclinical production in South Korea - CHOSUNBIZ - Chosunbiz
ST Pharm begins Nipah mRNA vaccine preclinical production in South Korea - CHOSUNBIZ biz.chosun.com
Korea’s pharma ramps up capacity to win global orders amid pricing shifts - CHOSUNBIZ - biz.chosun.com
Korea’s pharma ramps up capacity to win global orders amid pricing shifts - CHOSUNBIZ Chosunbiz
Frequently Asked Questions About ST Pharm
What is ST Pharm's CDMO Signal Score?
ST Pharm has a Signal Score of 73/100, based on quality, operations, financial stability, and capacity data.
Evaluating ST Pharm for a manufacturing program?
Use the free AI matchmaker to compare ST Pharm against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
Similar CDMOs
Corden Pharma
Plankstadt, DE · Caponago, IT · Boulder, CO
Signal Score: 81.1
mRNA, Oligonucleotide, Biologics
Nitto Denko Avecia
Milford, MA
Signal Score: 80.3
Oligonucleotide, mRNA
Kaneka Eurogentec
Seraing, BE
Signal Score: 80.3
mRNA, Plasmid, Oligonucleotide
Curia (RNA/Advanced)
Albany, NY · Albuquerque, NM
Signal Score: 79.4
mRNA, Oligonucleotide, Biologics
TriLink BioTechnologies
San Diego, CA
Signal Score: 71.0
mRNA, Oligonucleotide